Clinical Safety Protocol · High-Alert Vesicants

Extravasation Management: Staging, Antidotes & Bedside Protocols

A definitive evidence-based protocol for differentiating peripheral infiltration from vesicant extravasation, administering targeted pharmacological antidotes, and preventing permanent soft tissue necrosis.

Clinical Peer Review: Arthur Vance, MD, FACP Published: October 2026 Verified Board Member →
Vesicant extravasation clinical management tray with hyaluronidase antidote and calipers
Clinical Toxicology Monograph · Vesicant Antidote Kit & Diagnostic Calipers

1. Physicochemical Vesicant Taxonomy & Cellular Cytotoxicity

Vascular extravasation represents an acute medical emergency occurring in 0.1% to 6% of peripheral intravenous infusions and up to 0.5% of central venous line therapies. The pathophysiology of tissue destruction varies fundamentally depending on the chemical structure, binding affinity, and osmolar characteristics of the escaped agent.

Clinical practice recognizes three primary toxicological classes of vesicants:

Vesicant Toxicological Taxonomy:

  • A. DNA-Binding Vesicants (Anthracyclines & Alkylating Agents): Agents including Doxorubicin, Daunorubicin, Epirubicin, Idarubicin, and Mitomycin-C enter surrounding subcutaneous tissue and immediately intercalate between DNA base pairs, generating topoisomerase II cleavage complexes that trigger immediate cellular apoptosis. As the affected cells necrose and lyse, the persistent drug molecules are released back into the surrounding extracellular matrix intact. This establishes a self-perpetuating, progressive cycle of tissue necrosis that widens and deepens over weeks to months, frequently advancing to tendon, nerve, and periosteal destruction requiring extensive surgical debridement and plastic flap reconstruction.
  • B. Non-DNA-Binding Vesicants (Plant Alkaloids & Taxanes): Plant alkaloids (Vincristine, Vinblastine, Vinorelbine) and taxanes (Paclitaxel, Docetaxel) disrupt microtubule polymerization and spindle apparatus function without binding directly to cellular DNA. Cellular death causes local blister formation, ulceration, and severe chemical cellulitis; however, because the drug molecules are rapidly metabolized and cleared by local tissue macrophages, the ulceration does not expand indefinitely. Tissue damage is self-limiting provided secondary infection is averted.
  • C. Non-Cytotoxic Vesicants (Vasopressors & Hyperosmolar Agents): Vasopressors (Norepinephrine, Epinephrine, Phenylephrine, Dopamine) induce intense, sustained alpha-1 adrenergic vascular constriction, completely shutting down local microvascular capillary perfusion and producing acute ischemic tissue gangrene within hours. Hyperosmolar agents (Calcium Chloride 10% [2,040 mOsm/L], Dextrose 50% [2,525 mOsm/L], Sodium Bicarbonate 8.4% [2,000 mOsm/L], Potassium Chloride >2 mEq/mL) trigger massive intracellular-to-extracellular osmotic fluid shifts, rapid cellular dehydration, endothelial denudation, and chemical calcinosis cutis.
Extravasation Vesicant Classification & Antidote Matrix Four-column clinical emergency decision matrix categorizing DNA-binding vesicants, non-DNA-binding vesicants, vasopressors, and hyperosmolar agents with specific thermal compress protocols and targeted antidotes. EMERGENCY PHARMACOTHERAPY · ONS / ESMO GUIDELINES Extravasation Vesicant Classification & Antidote Matrix Differentiating cellular toxicity mechanisms, thermal applications, and specific antidote interventions DNA-BINDING VESICANTS High-Risk Agents: • Doxorubicin (Adriamycin) • Daunorubicin, Epirubicin • Mitomycin-C, Dactinomycin PATHOPHYSIOLOGY: DNA intercalation. Dead cells release drug; produces chronic, deep progressive ulceration. THERMAL COMPRESS: ❄ DRY COLD PACK 15-20m qid x 48h SPECIFIC ANTIDOTE: Dexrazoxane IV (Totect / Savene) Start <6 hrs: 1000 mg/m² BEDSIDE RULE: Aspirate 3-5 mL; DO NOT FLUSH. Preserve catheter for antidote. NON-DNA-BINDING High-Risk Agents: • Vincristine, Vinblastine • Vinorelbine, Vinflunine • Paclitaxel, Docetaxel PATHOPHYSIOLOGY: Mitotic spindle arrest. Does not bind DNA; cleared locally without chronic ongoing propagation. THERMAL COMPRESS: 🔥 DRY WARM PACK NEVER COLD! SPECIFIC ANTIDOTE: Hyaluronidase SC 150 to 1,500 Units Clockwise SC around site BEDSIDE RULE: Cold pack accelerates necrosis! Warmth promotes vasodilation. VASOPRESSORS / INOTROPES High-Risk Agents: • Norepinephrine (Levophed) • Epinephrine, Vasopressin • Dopamine, Phenylephrine PATHOPHYSIOLOGY: Alpha-1 hyperactivation causing intense local vasoconstriction, ischemic gangrene & necrosis. THERMAL COMPRESS: 🔥 DRY WARM PACK NO COLD! SPECIFIC ANTIDOTE: Phentolamine Mesylate 5-10 mg in 10 mL NS SC Infiltrate ischemic rim <12h BEDSIDE RULE: Reverses ischemia immediately. Topical Nitroglycerin 2% alternative. HYPEROSMOLAR / SALTS High-Risk Agents: • Calcium Chloride 10% • TPN (>900 mOsm/L), D50W • Hypertonic Saline 3% PATHOPHYSIOLOGY: Extreme osmotic gradient; draws intracellular fluid; calcium tissue precipitation & compartment edema. THERMAL COMPRESS: ❄ COLD / ELEVATE Agent Specific SPECIFIC ANTIDOTE: Hyaluronidase SC Sodium Thiosulfate 1/6 M (For Calcium Precipitates) BEDSIDE RULE: Elevate limb above heart level. Monitor compartment pressure. CRITICAL BEDFLOW MANDATE: Cease infusion immediately. Disconnect tubing from catheter. Aspirate residual lumen contents (3-5 mL). DO NOT FLUSH LINE.
Source: European Society for Medical Oncology (ESMO) & Oncology Nursing Society (ONS) Extravasation Guidelines (Pérez Fidalgo et al., Ann Oncol 2012). Emergency Clinical Monograph

2. Bedside Staging & Early Recognition (INS Standard 44)

The Infusion Nurses Society (INS) 2024 Standards of Practice define a 5-tier clinical staging scale from Grade 0 (no complication) through Grade 4 (severe extravasation). Early recognition is paramount: subtle warning signs include skin blanching halos around the catheter puncture, resistance to gentle syringe aspiration, and patient reports of acute stinging or burning.

CRITICAL CLINICAL OVERRIDE RULE (INS STANDARD 44):

Any extravasation involving a vesicant, blood product, or concentrated irritant solution is automatically classified as Grade 4 Extravasation regardless of gross edema radius or visual appearance. Immediate emergency antidote protocols must be activated without delay.

3. Definitive Antidote Pharmacology & Thermal Compress Protocol

TABLE 1: DEFINITIVE VESICANT EXTRAVASATION ANTIDOTE & THERMAL DIRECTIVES
ONS Guidelines · ESMO-EONS Standards · INS Standard 44
Vesicant Category & Representative Agents Specific Pharmacological Antidote & Regimen Thermal Protocol & Rationale Strict Contraindications
Anthracyclines
(Doxorubicin, Daunorubicin, Epirubicin)		 Dexrazoxane (Totect / Savene) IV:
Administer via IV infusion over 1–2 hours into a large vein in an unaffected limb. Initiate within 6 hours of extravasation.
• Day 1: 1,000 mg/m² (max 2,000 mg)
• Day 2: 1,000 mg/m² (max 2,000 mg)
• Day 3: 500 mg/m² (max 1,000 mg)
Alternative if unavailable: Topical DMSO 99% (4 drops per 10 cm² skin area q8h x 14 days; allow to air dry).		 DRY COLD COMPRESS:
Apply dry cold packs for 15–20 minutes, 4 times daily for 24–48 hours. Induces local vasoconstriction, concentrating the vesicant and retarding cellular uptake.
Note: Remove cold pack at least 15 min prior to Dexrazoxane infusion to restore tissue perfusion.		 NEVER apply warm compresses. Heat increases local tissue perfusion and accelerates anthracycline uptake into adjacent healthy cells.
Do not apply topical DMSO concurrently with Dexrazoxane.
Vinca Alkaloids
(Vincristine, Vinblastine, Vinorelbine)		 Hyaluronidase Subcutaneous:
150 to 1,500 Units (typically 1 to 2 mL of 150 U/mL solution). Inject 0.2 mL aliquots circumferentially into the subcutaneous tissue around the extravasation perimeter using a 25G or 27G needle. Change needle between punctures to avoid tracking drug.		 DRY WARM COMPRESS:
Apply dry warm packs for 15–20 minutes, 4 times daily for 48 hours. Induces vasodilation, increasing microvascular blood flow to dilute and rapidly carry away the alkaloid molecules.		 COLD IS STRICTLY CONTRAINDICATED! Cold application induces vasoconstriction, trapping the vinca alkaloid in tissue and dramatically compounding ulceration and necrosis.
Alpha-1 Vasopressors
(Norepinephrine, Epinephrine, Dopamine)		 Phentolamine Mesylate Subcutaneous:
5 to 10 mg reconstituted in 10 mL of 0.9% Normal Saline. Infiltrate subcutaneously throughout the ischemic, blanched area using a fine-gauge needle (25G–27G) within 12 hours of extravasation. Produces immediate hyperemic flushing and reverses ischemia.		 DRY WARM COMPRESS:
Apply warm compresses to facilitate collateral vasodilation.		 Do not apply cold packs. Do not inject into fingers or toes if localized digital vasospasm exists.
Alkylating Agents
(Mechlorethamine, Cisplatin >20 mL / >0.5 mg/mL)		 Sodium Thiosulfate (1/6 Molar solution):
Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water. Inject 2 mL subcutaneously per estimated 1 mL of extravasated drug. Thiosulfate provides an alternative substrate for alkylation, neutralizing reactive carbocations.		 DRY COLD COMPRESS:
Apply dry cold pack for 15–20 minutes q4h x 24–48h.		 Do not exceed recommended thiosulfate concentration; causes local hyperosmolar irritation.
Hyperosmolar Solutions
(Calcium Chloride 10%, Dextrose 50%, TPN)		 Hyaluronidase Subcutaneous (150–300 U):
Hydrolyzes hyaluronic acid in the extracellular matrix, facilitating rapid systemic absorption and tissue dispersion of the hyperosmolar fluid pool.		 DRY WARM COMPRESS & ELEVATION:
Elevate extremity above heart level for 48 hours; apply warm compress.		 Never massage the site mechanically; forces hyperosmolar fluid into deep fascial compartments.

4. Bedside Nursing Emergency Action Cascade (The Non-Coring Aspiration Protocol)

The 8-Step Emergency Bedside Action Cascade:

  1. Immediate Pump Cessation: Halt the infusion pump immediately upon the first patient complaint of stinging, burning, swelling, or unexplained line resistance. Disconnect the administration set.
  2. Leave Catheter in Situ: Do NOT pull the peripheral cannula or Huber needle immediately.
  3. Syringe Aspiration: Attach a sterile, needleless 3 mL or 5 mL luer-lock syringe to the catheter hub. Gently pull back on the plunger to aspirate as much residual medication and blood as possible (typically 2 to 5 mL).
  4. Instill Intraluminal Antidote (if indicated): If an antidote is to be delivered through the catheter (e.g., sodium thiosulfate), deliver it prior to catheter removal.
  5. Slow Needle Withdrawal: Withdraw the catheter or Huber needle slowly and steadily. Do not apply heavy digital pressure over the site, which drives vesicants deeper into fascial planes.
  6. Circumferential Subcutaneous Infiltration: For hyaluronidase or phentolamine, utilize a "pin-cushion" technique. With a 25G or 27G needle, inject 0.2 mL blebs into healthy tissue 5 mm outside the erythematous/blanched margin, encircling the entire site in a clockwise pattern.
  7. Limb Elevation & Thermal Application: Elevate the extremity above heart level for at least 48 hours to mobilize fluid and reduce compartment pressure. Apply dry cold or warm compresses per Table 1.
  8. Medical Photography & Staging: Demarcate the outer boundary with an indelible surgical skin marker. Measure length and width in centimeters. Photograph with a disposable paper ruler. Document under INS Grade 4 Extravasation. Notify the attending oncologist and hospital risk management.

Evidence Base & Literature Citations

  1. Pérez Fidalgo JA, et al. Management of chemotherapy extravasation: ESMO–EONS Clinical Practice Guidelines. Ann Oncol. 2012;23(suppl 7):vii167-vii173. DOI: 10.1093/annonc/mds294
  2. Infusion Nurses Society. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S):S1-S228. DOI: 10.1097/NAN.0000000000000532
Clinical Practice Boundary Notice

This protocol provides evidence-based guidance reflecting INS 2024 Standards of Practice and CDC recommendations. Clinical judgment, institutional policy, and patient-specific variables must guide individualized bedside care.